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Clinical trials in South Africa: Need for 
capacity building and training
To the Editor: The Lancet recently highlighted the importance 
of prioritising clinical research in South Africa.1 However, 
public hospitals do not encourage young medical professionals 
into clinical research. A plan to revitalise clinical research in 
South Africa is urgently needed.2
The focus of research and development (R&D) in South 
Africa is clinical trials.3 The South African Clinical Research 
Association (SACRA) estimates that in 2008 approximately 
R2.2 billion was generated through conducting internationally 
sponsored RCTs.4 This figure was limited by local regulatory 
approval times and insufficient suitable research sites. 
The Medicines Control Council (MCC) has recently made 
significant strides in reducing approval times. The deficiency in 
suitable trial sites must be addressed specifically by increasing 
capacity.
International sponsors have favoured South Africa 
for research as the population is genetically and socio-
economically diverse, relatively drug-naïve and in need of 
safe and effective therapies for a broad range of diseases.5 
Moreover, South Africa has a sound regulatory framework 
and efficient telecommunications, stipulates mandatory good 
clinical practice (GCP) training with 3 yearly updates, and is 
widely English-speaking.
The future of clinical trials depends on many factors, 
including recruitment efficiency and quality data. Despite 
recent growth in the industry, clinical research is not recognised 
as a speciality with formalised training (other than GCP), and 
proven expertise and competence is not assessed.6 Training 
programmes and certification processes must be standardised, 
with a core curriculum and reliable accreditation. Such training 
would improve investor and patient confidence and promote 
the generation of quality data. An increase in the number of 
trial sites would also increase patient recruitment potential 
and contribute towards capacity building. Such training is 
neither easily defined nor easily accessible. Internationally, a 
Masters in Public Health is regarded as the traditional degree 
for clinicians interested in research. International associations 
offering investigator certification programmes include the 
American Clinical Research Professionals (ACRP), the Society 
of Clinical Research Associates (SoCRA) and the Drug 
Information Association (DIA);7,8 however, a minimal number 
of researchers obtain such certification.
Recently, several foreign universities have been offering 
master’s degrees in clinical research, and the Royal Colleges 
of Physicians’ Faculty of Pharmaceutical Medicine offers 
a Diploma in Pharmaceutical Medicine. In South Africa, 
numerous GCP courses are offered9 and specific clinical trial-
related courses are slowly emerging. The Health Science 
Academy offers a course entitled Introduction to Clinical 
Research and another in Project Management for Clinical 
Trials. The Wits Health Consortium recently launched a quality 
control course for research sites; future courses include Starting 
Up a Research Site. Stellenbosch University offers a post-
graduate Diploma in Pharmaceutical Medicine.
Clinical research is finally starting to receive the recognition 
it deserves. For the industry to be regarded with academic 
credibility, we must generate original research in peer-reviewed 
journals. Editors have previously not been amenable to 
publishing work of this nature, but there is gradual progress in 
this area. Additionally, we need to focus on capacity-building 
conferences where we can share information with colleagues in 
the industry.
For clinical trials to grow, standardised training and 
accredited certification processes must be implemented, which 
would foster sponsor investment, promote patient confidence 
and, above all, ensure rigorous data quality and integrity – the 
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Surviving in the public sector
To the Editor: I have read the latest Med-e-Mails from SAMA 
with increasing distress. The apparent failure of our new 
Minister of Health to solve the problem of enabling doctors to 
negotiate just salary increases, because of labour legislation, 
is sad indeed. The obvious anger that this has evoked among 
members of the profession is very serious. It is awful to 
hear threats of resorting to strike action once more in this 
essential service. We can expect that the brain drain will again 
accelerate.  Medical and nursing staff who decide to stay in 
the service for love of our people will be increasingly open to 
burn-out and discouragement.  
My experience of 48 years in the public health structures of 
this nation suggests that those who stay will not find help in 
coping from the Department of Health. Those sensitive to their 
neighbours’ pain then often find the situation intolerable – they 
have to opt out for their own well-being. My own experience 
of that, as a gynaecologist in a rural KZN town, came in 2001. 
Dealing with as many as 120 child rapes per annum over a 
period of 10 years upset me so much that I had to pass this 
important and difficult work on to more junior staff with less 
experience. Now, with more time to consider the problem, I 
realise that medical staff in public hospitals must take care 
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to structure their own support, which can be done in several 
ways.
Those of us who are members of faith communities will 
usually be able to find a mentoring individual or group to 
provide a secure place where we can off-load and find objective 
insights to help deal with our own pain.
In the 60s and 70s, in a deep rural mission hospital, our 
weekly journal club was run in such a way that we could give 
one another mutual support. That sometimes included insisting 
that someone take time off.  We were a small group of 5 doctors 
looking after 550 inpatients. But there is no reason why like-
minded doctors should not form small support groups even 
in the largest hospital. That is better than always taking flight 
from a difficult situation without helping one another to make 
it more bearable.
Any person who becomes aware that they are suffering from 
significant burn-out (illogical rage reactions, sleep disturbances, 
depression, etc.) should seriously consider seeking the help 
of a psychologist. That decision has significant financial 
implications, but if one chooses the right colleague, it will be 
well worth the expense.
These and other similar solutions should be sought in good 
time by all who feel strong enough and who desire to stay and 
work for our people. It is often too late to begin when one is 
actually in crisis. In that situation, the only sensible way to 
cope may be to leave!
J V Larsen





To the Editor: Meckel’s diverticulum, a true congenital 
diverticulum, is a small bulge in the intestine present from 
birth.  It is a vestigial remnant of the original yolk sac or 
vitello-intestinal duct1 and was originally described by Johann 
F Meckel in 1809.2,3
I present a case of Meckel’s diverticulitis in a 4-year-old 
boy who presented with overt iron deficiency anaemia. 
Ferritin levels were low and the peripheral blood showed a 
hypochromic, microcytic anaemia consistent with an iron-
deficient picture. The haemoglobin concentration was 10 g/dl. 
He had a bright red melaena stool and right iliac abdominal 
pain. A barium meal showed Meckel’s diverticulitis. The 
Meckel’s diverticulum and adjacent ileum were successfully 
removed surgically.  
Meckel’s diverticulum is found in 2% of the population, 
more frequently in males; it is usually 2 foot from the ileo-
caecal valve and 2 inches in length (the rule of the 2s). The 
diverticulum usually contains oxyntic cells from gastric mucosa 
that cause an ulcer giving rise to intestinal bleeding. The 
diverticulum may contain pancreatic tissue and may obstruct 
or strangulate in a type of volvulus. 
This patient presented with iron deficiency anaemia, but 
Meckel’s diverticulitis can often simulate acute appendicitis. 
It is generally not necessary to remove Meckel’s diverticula 
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Mercury exposure in a low-income  
community in South Africa
To the Editor: I read the recent article on mercury exposure 
with a great interest.1 Oosthuizen et al. concluded that ‘As 
primary health facilities will be the first point of entry for 
individuals experiencing symptoms of mercury poisoning, 
South African primary health care workers need to take 
cognisance of mercury exposure as a possible cause of 
neurological symptoms in patients.’1 
I would like to contribute some thoughts on the subject. 
Firstly, not only recognition of the problem but also close 
surveillance is required. Indeed, the problem can be expected, 
based on the nature of the factory. If it holds risk of mercury 
exposure, monitoring the environment as well as workers and 
the nearby population is recommended. These issues continue 
to be problems in actual practice in developing, poor countries 
in Africa and Asia. Secondly, there are many other toxic 
substance that can cause neurological symptoms. The complete 
differential diagnosis of other possible causes of intoxication 
and further medical disorders is still important for the primary 
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